<I>In vitro</I> activity of panipenem against clinical isolates in 2006

DOI Web Site 2 Citations 25 References
  • YOSHIDA SANAE
    Post-Marketing Study Department, Daiichi Sankyo Co., Ltd.
  • KOGA TETSUFUMI
    Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd.
  • KAKUTA MASAYO
    Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd.
  • KOBAYASHI INTETSU
    Chemotherapy Division, Mitsubishi Chemical Medience Corporation
  • MATSUZAKI KAORU
    Chemotherapy Division, Mitsubishi Chemical Medience Corporation
  • URABE ERIKO
    Chemotherapy Division, Mitsubishi Chemical Medience Corporation
  • OMIKA KAORU
    Chemotherapy Division, Mitsubishi Chemical Medience Corporation
  • HASEGAWA MIYUKI
    Chemotherapy Division, Mitsubishi Chemical Medience Corporation
  • SATO YUMIE
    Chemotherapy Division, Mitsubishi Chemical Medience Corporation

Bibliographic Information

Other Title
  • 2006年臨床分離株に対するpanipenemの抗菌力
  • 2006ネン リンショウ ブンリカブ ニ タイスル panipenem ノ コウキンリョク

Search this article

Abstract

The antimicrobial activity of various antibiotics against clinical bacterial isolates recovered from patients with infectious diseases at the medical facilities in the Kanto region between March and September 2006 was evaluated. A total of 1030 clinical isolates were available for susceptibility tests: 420 aerobic Gram-positive organisms, 520 aerobic Gram-negative organisms, 30 anaerobic Gram-positive organisms and 60 anaerobic Gram-negative pathogens. Antimicrobial susceptibility data for Streptococcus pneumoniae and Haemophilus influenzae isolates from pediatric and adult patients were analyzed separately.<BR>Panipenem (PAPM), imipenem (IPM), meropenem (MEPM), biapenem (BIPM), doripenem (DRPM), cefozopran (CZOP), cefepime (CFPM), and sulbactam/cefoperazone (SBT/CPZ) were used as test antibiotics.<BR>PAPM, IPM and DRPM exhibited excellent in vitro antibacterial activities against methicillin-susceptible Staphylococcus, with all isolates exhibiting a MIC of ≤0.06μg/mL. Against Streptococcus including penicillin-resistant S. pneumoniae, PAPM demonstrated the strongest antibacterial activity among the carbapenems with a MIC range of ≤0.06 to 0.12μg/mL.<BR>Against Enterobacteriaceae, MEPM showed the strongest antibacterial activity, and PAPM had comparable activity to IPM. Against the extended-spectrum β-lactamase producing Escherichia coli, Klebsiella species and Proteus species, the MICs for the cephems were high, however, those for the carbepenems were low. Against H. influenzae, PAPM had comparable activity to IPM.<BR>With respect to anaerobes, each of the carbapenems tested demonstrated almost the same strong antibacterial activity.<BR>In conclusion, 13 years has passed since PAPM was launched in 1993, PAPM still maintains potent antibacterial activity and is considered an effective antimicrobial agent for various types of infectious diseases.

Journal

Citations (2)*help

See more

References(25)*help

See more

Details 詳細情報について

Report a problem

Back to top